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Abstract 
A better understanding of cancer biology has led to the development of 
targeted anticancer drugs. However, the full potential of these agents 
has not been realised due to the presence of de novo resistance, often 
resulting from compensatory signalling pathways or the development of 
acquired resistance in cancer cells that undergo clonal evolution under 
selective pressures of treatment. Combinations of targeted treatments 
can circumvent some mechanisms of resistance yielding clinical 
benefit. We explore the challenges of how to identify the best drug 
combinations, the best combination strategies, and the complexities of 
delivering these to patients. Recognizing treatment-induced toxicity and 
the inability to use continuous pharmacodynamically effective doses of 
many targeted treatments needs creative intermittent scheduling. Serial 
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tumour profiling and the use of parallel co-clinical trials contribute to 
understanding mechanisms of resistance, and will guide the 
development of adaptive clinical trial designs that can accommodate 
hypothesis testing, to enable the full potential of combination therapies.  
 
Introduction 
A better understanding and characterisation of cancer cells, their 
microenvironment, and their interaction with the host immune system 
has resulted in a paradigm shift in the way new cancer therapies are 
developed.[1] Over the past 20 years, the focus of new drug 
development has been on the known oncogenic drivers. Notable 
success examples have included the high rate of cytogenetic response 
rates and long-term remissions seen patients with BCR–ABL driven 
chronic myeloid leukaemia (CML) treated with imatinib [2]. While 
imatinib is regarded the poster child of the ‘one genetic abnormality - 
one drug’ drug development paradigm, in reality the efficacy seen was 
the exception rather than a rule and reflects the biological complexity 
that governs the vast majority of cancers. As our arsenal of targeted 
anticancer agents grows, despite the promise observed in preclinical 
experiments and initial high response rates, a large number of targeted 
drugs (such as PI3K, AKT, MET and IGFR inhibitors) have not been 
successful in providing reproducible improvements in survival in 
patients with cancer when used as single agents [3-5]. The good 
intentions but unrealistic expectation set by the early success of 
imatinib in CML have been sobering, and some might posit they have 
led to premature termination of the development of classes of drugs 
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such as IGF/IGFR inhibitors because they did not show single agent 
activity [6].  
 Efforts focussed on identifying small subsets of tumours 
hypersensitive to these drugs in ‘basket’ studies have yielded some 
benefit,[7, 8] but these approaches may not be constitute commercially 
viable strategies to help patients with cancer. This is, in part, because 
intrinsic or de novo resistance is a major reason for treatment failure 
and, in some instances, has been successfully overcome by a 
combination therapy approach, either with chemotherapy (such as 
rituximab with chemotherapy) [9, 10] or with other targeted treatments 
(such as everolimus with letrozole).[11] In addition, a large number of 
mechanisms of acquired resistance have emerged that exist in clones 
of tumour cells that have evolved and proliferated under the selective 
pressure of effective treatment.[12-15] While some mechanisms of 
acquired resistance are due to the presence of events that make the 
drug ineffective against its target (for example, the development of 
T790M mutations in cancer cells that cause resistance to first-
generation EGFR inhibitors, such as erlotinib and gefitinib) [16, 17], 
some of these mechanisms of resistance still enable a drug to be 
effective against its target but might make the tumour become resistant 
in time owing to compensatory signalling (such as MEK signalling in 
BRAF-driven melanoma treated with BRAF inhibitors).[18-21] It is 
possible to make a difference in this latter category , and use a ‘window 
of opportunity’ to prevent development of acquired resistance by 
combining targeted agents, such as the combination of BRAF and MEK 
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inhibitors, to circumvent compensatory pathway activation, which has 
shown improved overall survival in melanoma BRAF mutant melanoma. 
[22-24]  
Hence, a focus on understanding mechanisms of de novo and 
acquired resistance is required to translate the preclinical promise of 
these targeted anticancer drugs when used in combination into 
strategies that can be registered in trials. In devising combination 
studies, the strategies should be judged by the ultimate impact made 
on the patient’s tumour. This can range from and number of 
approaches. First, synthetic lethality where drugs as single agents 
have minimal effects, to significant antitumour activity when a genomic 
defect or compensatory pathway is targeted therapeutically in 
combination. Second, the concept of synergy, where one or all partners 
in the combination have some clinical activity, but that the sum of 
clinical activity is greater than the effect of each individual drug (the 
whole if greater than the sum of its parts). Third, additivity, where the 
effect on the tumour is equal to the sum of activities of both drugs. 
Finally, mild antagonism, where the sum of activity of all drugs in the 
combination is less than the sum of activity of individual agents , but is 
more than each individual drug in the combination (FIG 1). Most 
targeted drug combinations in the clinic operate in the realms of 
additivity and mild antagonism; however, efforts are now focussed on 
identifying synthetically lethal or synergistic drug combinations. In the 
setting of metastatic (and, currently in most instances, incurable) 
disease, the clinical outcomes should not be based entirely on the 
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effects of the combination on the tumour, but should also consider the 
associated direct and indirect costs of toxicity to patients.  
 We have deliberately included discussion of only combinations of 
targeted anticancer agents with other anticancer agents, but not with 
chemotherapy to ensure the focus is retained. Researchers face 
complex challenges in designing and executing these drug 
combinations. We aim to define these challenges and propose creative 
strategies to implement them, with the eventual aim of improving 
outcomes in cancer patients.  
 
Challenges for targeted combinations   
There are two major challenges in developing drug combination 
strategies for treating cancer. The first challenge is to find the best 
drug combinations to explore. While relatively small hypothesis-testing 
combination experiments have resulted in successful combination 
strategies, for example the clinical co-targeting of MEK and AKT 
signalling in KRAS mutant tumours [25] the scale of the biological 
complexity of the mechanisms of resistance to targeted treatment is too 
large to be tackled by multiple single-hypothesis-testing experiments 
and instead requires novel approaches. Furthermore, there are 
hundreds of targeted treatments in development and in clinical 
evaluation and the number of combination trials outweigh  the number 
of patients who can be entered into trials to evaluate them [26]. Thus, 
experiments to discover and prioritize the optimal combinations for the 
treatment of patients with cancer are needed. The second challenge is 
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the difficulties involved in combining targeted anticancer agents in a 
clinical setting. Issues related to realising the full potential of 
combination therapy in the clinic using targeted anticancer agents 
include toxicity, pharmacokinetic interactions and finding the correct 
timing and context of using these combinations. We have focussed on 
addressing the two challenges above related to combination therapy 
using targeted anticancer agents. 
 
Challenge 1: the best combination  
Unbiased chemical screens 
Novel and unexpected drug combinations can be identified from 
unbiased high-throughput systems-based approaches.[26] Combination 
high-throughput screening of all FDA licensed drugs has been carried 
out to discover unexpected synergistic interactions, as exemplified by 
the combination of the anti-parasitic drug pentamidine with 
antipsychotic chlorpromazine that that has synergistic anti-mitotic 
activity in vitro [27, 28]. In some instances, the use of unbiased 
modelling on the basis of reported clinical adverse effects  has been 
used to predict the tolerability of a drug combination [29, 30] but it 
remains to be seen if clinically efficacious combinations can be 
identified by such an approach. One limitation of this strategy is its lack 
of mechanistic insight, for example, an anti-helminthic that is designed 
to remain extracellular is unlikely to have in vivo activity in humans. An 
alternative to chemical screening would be the systematic genome-
wide loss-of-function screens that are utilized to assess the role of 
  7 
specific target genes in tumour cells and rapidly identify novel drugs for 
combination [31].  
  
Synthetic lethality and siRNA screens  
The concept of synthetic lethality originates from studies in Drosophila 
model systems in which a combination of mutations in two or more 
separate genes leads to cell death and exploits inherent differences 
between cancer cells and normal cells.[32] Genome-wide short hairpin 
RNA (shRNA) and small interfering RNA (siRNA)–mediated synthetic 
lethal drug-sensitization screens are uncovering novel therapeutic 
combinations that can be targeted to oncogenic drivers, including those 
previously thought to be undruggable, such as KRAS.[33, 34] 
Investigators screened human non-small-cell lung cancer (NSCLC) cell 
lines carrying either wildtype or mutant KRAS with an siRNA library 
developed against 7,000 human genes and uncovered a novel 
synthetic lethal interaction between the DNA transcription factor 
GATA2 and oncogenic KRAS.[35] It was not possible to directly drug 
GATA2, which is a transcription factor, but combined gene-expression 
analysis and chromatin-occupancy analysis revealed a broad network 
of pathways controlled by GATA2 in RAS-pathway mutant NSCLC 
cells, which included NF-κB and RHO-related signalling pathways. The 
combined inhibition of the proteasome and Rho/ROCK signal ling with 
the clinical compounds bortezomib (a proteasome inhibitor) and the 
Rho-kinase inhibitor fasudil led to almost complete regression of well-
established lung tumours in a KRAS-driven mouse model[35]. There 
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are currently clinically licensed proteasome inhibitors [36], and 
although ROCK inhibitors are being developed for use in cancer and 
have not yet been tested in the clinic, this combination could be 
exemplar of this approach of finding combinations to treat KRAS 
mutant cancers—an area of unmet need. 
 A more-common strategy for identifying potential drug 
combinations uses RNA interference (RNAi) to simulate models of 
pharmacological inhibition. In this method, wild-type cell lines or cell 
lines with induced loss of function for a particular target are screened 
against RNAi libraries with or without exposure to a particular drug to 
look for synergism or drug sensitization.[37, 38] An example is the 
large-scale unbiased combinatorial drug screen to identify cocktails  
active against melanomas with activating BRAF or RAS mutations, 
including those with intrinsic or acquired resistance to the approved 
BRAF inhibitor vemurafenib. This identified a triple combination, 
involving BRAF, EGFR and AKT inhibition, which was highly effective 
in BRAF-mutant melanomas and overcame vemurafenib resistance in 
vitro. Moreover, it revealed that combinations of statins and pan-CDK 
inhibitors were effective in NRAS-mutant melanomas.[39] Of note, the 
effective combinations were not predicted by single-agent screening, 
which highlights the potential for this approach to identify novel 
feedback signalling circuits and nodes that can be targeted by 
synergistic drug combinations.  
 SiRNA screens can also be used to understand and solve 
mechanisms of resistance in different tumour contexts. For example, 
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BRAF inhibitors are successful in treating BRAFV600E mutant 
melanoma [40], but not BRAFV600E mutant colorectal cancer.[41] A 
focused kinase siRNA screen showed that knockdown of EGFR was 
synthetically lethal with vemurafenib treatment in BRAFV600E mutant 
colorectal cancer cells suggesting that the combination therapy of 
BRAF and EGFR inhibitors may be clinically beneficial.[42]. 
Subsequently, dual RAF and EGFR inhibition led to improved in vivo efficacy 
in BRAF mutant CRC xenografts and multiple clinical groups are 
exploring this combination in hypothesis-testing clinical trials 
(NCT01719380, NCT01791309, NCT01750918) and preliminary results 
suggest clinical activity [43 , 44, 45].  
 Although siRNA screens are powerful to identify and validate 
novel targets, there remain significant limitations.[46] Firstly, siRNA 
inhibition can have off-target effects, or only partially knock-down the 
protein of interest. This might be overcome by the advancement of 
CRISPR-Cas9 genome-editing technologies that can complement and 
verify targets.[47, 48] Second, silencing of gene expression, and the 
loss of all functions of the protein, may not recapitulate the effects of 
targeting a single function of the protein, such as a kinase activity.  
 
[H2] Systems biology 
Systems-biology approaches involve analysis of a plethora of data, 
which could be genetic, transcriptomic, proteomic or factors that affect 
post-translational modification.[49] Different computational models can 
be created, iteratively refined and implemented. Examples of models 
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include Bayesian, logic based or mass action models to analyse 
phosphoproteomic data and to provide a testable hypothesis for 
combinations to overcome resistance to targeted anticancer 
agents.[26, 50, 51]. Some approaches study the importance of proteins 
in intracellular networks and are used to inform on combinations of 
drugs outside of traditional portfolio of anticancer drugs based on 
differences these drug targets make on the intracellular 
interactome.[52] One recent study benchmarked the ‘ideal’ state of 
genetic extinction of mutant NRAS in a mouse model, and identified the 
drug combination of MEK and CDK4 inhibitors as most closely 
approximating the transcriptomic landscape of NRAS extinction, 
thereby proposing a workable hypothesis using this combination of 
targeted anticancer drugs to develop a clinically effective 
combination.[53] This benchmarking approach also enables the 
flexibility to adapt the design of combinations to address issues of 
tumour heterogeneity.[54] While, thus far, these data sets have 
involved the interpretation of biological data using machine-learning 
algorithms, future applications could involve the use of artificial 
intelligence.  
 Systems biology approaches have also directed researchers 
towards drug combinations of targeted agents and agents that target 
epigenetic mechanisms. Examples include combinations targeting 
HER2 and BET bromodomain inhibitors or BRAF and BET 
bromodomain inhibitors in breast cancer and melanoma, 
respectively.[55, 56] This strategy of targeting a node in the network, 
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such as MEK or RAF in combination with a second agent that has 
broader epigenetic or post-translational effects (for example, BET 
bromodomain, HDAC or HSP90 inhibitors) is an emerging theme in 
preclinical experiments.  
 Translating systems biology approaches has significant 
challenges. The results from such studies need to be validated in 
preclinical experiments and then distilled into clinically usable 
combinations in subsets of patients defined by biomarkers. However, if 
refined and distilled into clinically usable combinations, these 
approaches are likely to open up the possibilities of combinations of 
entire new sets of drugs and biological targets, currently overlooked by 
current approaches.  
 
Human tissue and primary cell-based assays  
Looking forward, disease models based on human samples that 
accurately reflect the complexity of human cancers will be critical to the 
success of the development of new drugs and combinations.  Large 
repositories of ‘established’ cell lines exist; however, there are 
significant differences in their genetic landscape when compared to 
tumour samples from patients [57]. Investigators are developing 
strategies to establish patient-derived cell culture models, for example, 
from biopsy samples of patients with lung cancer whose disease had 
progressed on EGFR or ALK inhibitors, and then testing them on a 
pharmacogenomic platform that facilitated the rapid discovery of 
multiple, effective drug combinations such as the combination of ALK 
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and SRC inhibitors. [58] While these models reflect the biological 
complexities of resistant human tumours better than established cell 
lines models, the results of randomized clinical trials remain to be seen 
to prove that drug combinations suggested by such experiments can 
change clinical outcomes. 
 Patient-derived xenografts (PDXs) are also emerging as a 
powerful tool for investigating tumour biology and resistance 
mechanisms because they more faithfully recapitulate the molecular 
diversity, cellular heterogeneity, and histology seen in patient 
tumours.[59-61] The power of PDXs in studying preclinical drug 
combination efficacy is illustrated by recent work studying a PDX model 
of EGFR mutant lung cancer that developed ERK1 and ERK2 signalling 
reactivation days following continuous treatment with an EGFR inhibitor 
[62] [57]. The combination of EGFR inhibition with MEK inhibition not 
only delayed the onset of resistance, but achieved cure some mouse 
xenograft models. Furthermore, tumours that were resistant to the dual 
combination were shown to have developed downstream mTOR 
activation, offering an avenue for further combination strategies. [62] 
The limitation currently is that the development and propagation of 
mouse models, PDXs and drug testing can take up to 6 months. With 
the development of PDX encyclopaedias [63] and improvements in 
efficiency, speed and cost, this technology is likely to yield exciting 
results that will directly impact upon patient care.  
 
Challenge 2: Executing the combination 
  13 
Once a rationally designed combination is selected, its early clinical 
development is a complex process that requires attention to detail . 
Many issues influence implementation of combination strategies that 
are indicated by well-conducted scientific experiments. These include 
toxicity, pharmacokinetic and pharmacodynamic interactions, the timing 
of the development of resistance and, finally, finding a robust 
biomarker to predict response. In our mind, there are three major 
challenges facing the clinical community when testing a drug  
combination: first, how do we implement the combination; second, 
when do we implement the combination; and third, in whom do we 
implement the combination. 
 
How to implement a drug combination 
The biggest challenge in developing combination therapies of targeted 
anticancer drugs is the narrow therapeutic index of each drug owing to 
overlapping toxicities.[64] In some instances it has been possible to 
combine the full dose of each targeted agent at the original schedule; 
for example, in the case of combining dabrafenib and trametinib, and 
vemurafenib and cobimetinib in the setting of malignant melanoma.[23, 
65-67] In addition to expected overlapping toxicities, unexpected 
toxicities relatively specific to the combination, such as fever have 
been observed.[66, 67] However, being able to deliver the 
recommended phase 2 dose of single agents within a combination is 
rare, and not infrequently, supra-additive toxicities are seen. [68] 
(TABLE 1). 
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 At present, preclinical models are not yet able to reliably predict 
toxicity [69], which adds to the challenge of optimising the toxicity-
efficacy balance of drugs given in combination. For example,  
combining drugs that inhibit the PI3K/AKT/mTOR and the oncogenic 
RAS/RAF/MEK/ERK networks are exciting because resistance to 
inhibition of one pathway is attributed to signalling crosstalk.[4] 
However, it has been exceedingly difficult to deliver full does of 
combinations of MEK and PI3K pathway inhibitors in the clinic because 
of overlapping toxicities caused by drugs that act on these targets. [70, 
71] For example, the adverse effects associated with PI3K inhibitors, 
such as hyperglycaemia, nausea, fatigue, rash and gastrointestinal 
toxicities, as well as rash, diarrhoea and dermatitis associated with 
MEK inhibition, illustrates the challenge in ongoing early phase dose-
finding trials that have not been able to define the doses of drugs 
which, as single agents, caused maximal pharmacodynamics effects 
because of dose-limiting toxicities. Rather, the trials to date have 
required multiple dose de-escalation steps to determine a tolerable 
dose (Figure 2A right panel).[25] Furthermore, continuous exposure to 
both PI3K and MEK inhibitors is not feasible in the clinical setting, with 
most patients requiring treatment interruptions and dose modifications 
with chronic dosing.[72]  
 Preclinical studies in a panel of cell lines quantifying the 
signalling transduction output of combined MEK and AKT inhibition in 
the background of specific driver mutations showed that sub-maximal 
inhibition of MEK and AKT pathways did not cause a significantly 
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greater growth inhibition compared with growth inhibition caused by 
maximal MEK or AKT inhibition alone[73]. This finding indicates that a 
more biological meaningful strategy to develop drug combinations 
would start with 100% of the optimal biological dose (OBD) of drug A 
and escalate drug B (Figure 2B) or use the daily OBDs of both drugs 
but escalate their schedule (Figure 2C).  
 Other issues that can influence how to combine targeted 
anticancer agents include pharmacokinetic (PK) interactions. For 
example, lapatinib is both a substrate and a moderate inhibitor of 
CYP450-3A4, and can significantly reduce the clearance of other drugs 
that are CYP450-3A4 substrates and vice versa.[74] A phase I trial of 
lapatinib and pazopanib compared PK parameters of the combination 
with historical data of the drugs and it was decided that combining 
them did not alter exposure of either drug.[75] However, more detailed 
subsequent PK analyses in a glioma patient population at the phase II 
recommended dose level indicated that there was a significant drug–
drug interaction leading to subtherapeutic lapatinib dosing[76] [72]. In 
addition, the frequent use of anti-epileptics in this population also 
decreased exposure to pazopanib leading to the poor outcomes 
seen.[76] This highlights the importance of incorporating detailed PK 
assessments into the evaluation of combinations of targeted anticancer 
agents.  
 
[H2] When to implement a drug combination 
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Initial studies recommending the dose and schedule of drugs in a drug 
combination are often conducted, and the dose determined, in the 
setting of advanced-stage disease. However, it is critical to define the 
setting for evaluating the efficacy of the combination in later phase 
clinical trials. The settings where combinations can be evaluated 
should be guided by the hypothesis being tested (Figure 3). 
 Firstly, is the combination being instituted to delay the onset of 
resistance rather than increase the degree of tumour shrinkage, that is, 
to increase the length rather than the depth of the response? For 
example, preclinical arguments have been put forward to pre-emptively 
combine HSP90 inhibitors with hormonal therapy or BRAF inhibitors to 
prevent the emergence of resistance.[77, 78] The HSP90 chaperone 
machinery ‘buffers’ disadvantageous metabolic and environmental 
stress within cancers cells caused by secondary mutations, which can 
lead to acquired resistance [79]. Inhibiting HSP90 prevents the 
evolution of such resistance clones and, therefore, these combinations 
are likely best evaluated in the frontline adjuvant or first -line metastatic 
setting.  
 Secondly, is the combination being tested because there is a 
degree of de novo resistance to one of the drugs that is being reversed 
by the addition of the second drug? Again, in this case the efficacy of 
the combination is best conducted in the first-line or neoadjuvant 
treatment setting, as shown with the addition of pertuzumab to 
trastuzumab and chemotherapy regimens.[80, 81] It could be argued 
that once patients have developed resistance to chemotherapy or 
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trastuzumab this combination is unlikely to succeed, as the addition of 
pertuzumab does not realistically reverse multiple mechanisms of 
acquired resistance to trastuzumab or chemotherapy. While a drug 
holiday can on occasion enable patients to regain sensitivity to the 
same drug, this is usually due to reversal of compensatory feedback 
loops and expansion of sensitive tumours clones.[82, 83] Another 
example is the lack of single-agent activity of MEK inhibitors in multiple 
settings, which is attributed to activation of signal transduction 
pathways, such as the PI3/AKT/mTOR pathways in light of de novo 
resistance.[84, 85] As this hypothesis involves reversal of de novo 
resistance, efficacy of these combinations is best conducted when MEK 
inhibitors are first used rather than in a setting when resistance has 
already occurred. Both these examples of using combinations to 
reverse de novo resistance predominantly increase the depth of the 
response, but as a consequence they improve progression-free survival 
rather than uniquely inhibiting the development of resistance. [25]    
 Lastly, is the combination being developed to reverse acquired 
resistance? The development of secondary mutations, gene 
amplifications and late activation of signal transduction pathways in 
tumour cells is a common feature in the development of acquired 
resistance [Ref]. Adding a second drug as part of the combination in 
this setting takes the dynamic nature of clonal evolution into 
consideration and assumes that the tumour consists of clones that are 
still sensitive to the first drug and that addition of the second drug to 
the therapy combination will target clones resistant to the first drug. An 
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example of this type involves the combination of HER2-targeting drugs 
in combination with mTOR inhibitors,[86-88] where secondary 
mutations in PIK3CA or increased signalling though PI3K has been 
shown to be a mechanism of acquired resistance in women with HER2-
positive advanced-satge breast cancer.[89] In the future, innovative 
clinical trial design in both these settings can involve adding the 
second drug when resistance has occurred following initial response to 
the first drug. It is, however, important that the second drug is added 
when there are still clones within the tumour that are sensitive to the 
first drug. This is greatly facilitated by the analysis of circulating tumour 
DNA (ctDNA).[90, 91] Such molecular studies can be used as cues to 
initiate a combination before resistance occurs. However, profiling of 
mutations in tumours is unable to guide combination strategies that 
target epigenetic alterations that rewire signal transduction as a 
mechanism of resistance.  
 
Implementing combinations and biomarker  
Biomarkers for positive selection of patients likely to respond to 
targeted treatment can include mutated genes (BRAF, EGFR), 
amplification (HER2) or translocations (ALK) or alterations in protein 
products (ER) [92-94] and there are a few examples of the use of such 
biomarkers for negative selection of patients for a particular therapy, 
such as the use of KRAS mutations to predict resistance to cetuximab 
in colorectal cancer. [95-97] However, such markers might not be 
useful to guide drug combinations. For example, although BRAF 
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mutation is now established as a biomarker for MEK inhibition,[98] and 
PI3K mutation for AKT inhibition,[4] recent work suggests that KRAS 
mutations are a biomarker for the successful use of a drug combinat ion 
of MEK and PI3K/AKT inhibitors.[99] Furthermore, the experience with 
MEK and AKT inhibitor combination regimens has revealed a potential 
lineage context of therapeutic importance; these combinations have 
shown preliminary antitumour activity in KRAS-mutant NSCLC and 
ovarian cancer, but not in colorectal cancer.[25, 99] Thus, there is a 
real unmet need to understand and develop robust biomarkers in the 
context of an evolving complex signalling network.  
 The increased use of reliable genetically-engineered mouse 
models and PDX models that reflect mutations for the study of drug 
combinations might also facilitate the more-rapid identification of 
potential biomarkers.[100, 101] For example, dual MEK and mTORC1/2 
blockade results in synergistic anti-proliferative effects in PDX models 
of colorectal cancer bearing alterations in KRAS/BRAF and 
PIK3CA/PTEN [102] [Ref]. However, this marked pro-apoptotic 
response to combination therapy was observed exclusively in wild-type 
P53 models, [102] suggesting that the combination of concomitant 
KRAS and PI3K mutations in a P53 wild-type setting could be 
predictive of clinical activity for the combination, and th is can easily be 
tested in early phase trials.  
 
The immune system and microenvironment  
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Another potential strategy that has garnered much attention is the use 
of combination cancer immunotherapy. The hypothesis that tumour cell 
death triggered by targeted therapies could result in antigen release 
and immunomodulation that could potentiate immune responses and 
enable eradication of tumour cells is exciting.[103-105] 
 Studies focusing on the specific mechanisms of tumour immune 
evasion are still at a relatively early stage. Although expression of both 
PD-1 and CTLA-4 dampens T-cell activation, we have yet to identify a 
robust signature of immune evasion and adaptive immune 
resistance.[106-108] For example, if there is a sufficient density of T 
cells in tumours that are turned off by adaptive immune resistance, PD-
1–PD-L1 combinations might be effective. If T cells have not made it 
into the tumour, or are unable to recognise tumour antigens, 
combination strategies that activate an immune response or manipulate 
the network of cellular interactions in the tumour microenvironment that 
converge to establish immune tolerance would be required. [109, 110]  
 Exciting recent work has uncovered the effect of oncogenic 
signalling pathways on the modulation of tumour–immune interactions, 
and indicates that the combination of targeted treatments with 
immunotherapy may be an effective approach for cancer treatment. For 
example, preclinical models of melanoma have shown that PTEN loss 
in tumour cells increases the expression of immunosuppressive 
cytokines resulting in decreased T-cell infiltration into tumours. [111]. 
Treatment with a PI3K inhibitor improved the efficacy of checkpoint 
inhibition in this model and this could be studied in hypothesis-testing 
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clinical trials. Other murine models of resistance to targeted 
treatments, such as imatinib have shown that resistance critically 
depends on indirect effects from the immune system and that 
concurrent administration of imatinib with checkpoint blockade can be 
synergistic,[112]. This possibility is now being pursued in an early 
phase trial (NCT01738139).[113]  
 While the use of PDX models based on patient samples 
harvested at diagnosis to study mechanisms of resistance are well 
known, their use in studying immune mechanisms of resistance are 
limited by the intrinsic murine immune system; thus, very complex 
mouse models will be required to exploit the use of PDXs in the setting 
of immunotherapy.  
 Despite concerns that immune checkpoint combinations can be 
overtly toxic, early studies of the combinations of the BRAF inhibitor 
vemurafenib with anti-PD-1 or anti-CTLA-4 antibodies showed they 
were reasonably tolerated, albeit with a significant incidence of 
unanticipated adverse events, such as hepatotoxicity, cutaneous and 
neurologic toxicities. [114] [115]. This situation might be due to the 
paradoxical ability of BRAF inhibitors to activate T-cells via ERK 
signalling, highlighting the need for careful assessment of the 
therapeutic indices of combinations of targeted treatments with 
immunotherapy.   
 Efforts are ongoing to identify biomarkers that can predict 
patients that are likely to respond to immunotherapy. Retrospective 
analyses suggest that the maximum benefits of dual anti-CTLA-4 and 
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anti-PD-1 therapy was seen in patients with tumours that were PD-L1 
negative, which if confirmed in future trials, suggests biomarkers are 
critical in choosing combinations with immune checkpoint regulators.   
 
Conclusions 
Thinking surrounding the development of anticancer strategies is 
evolving. The initial euphoria of early breakthroughs exploiting targeted 
treatments was followed by disappointment related to the observation 
of de novo resistance to large numbers of these agents and, later, 
acquired resistance in patients who had an initial response. While 
combinations of targeted therapies have made some inroads to 
address de novo and acquired resistance, we have faced considerable 
challenges and the full potential of combination approaches has not 
been realised.  
 We feel that there is reason to be optimistic. Newer technologies, 
such as the widespread use of gene-silencing tools, including shRNA 
and CRISPR to find synthetically lethal drug combinations, and 
phosphoproteomic technologies to understand and predict complex 
compensatory signalling mechanisms, will greatly enable researchers 
to propose and predict effective combinations that would not have 
come to light or would have been much slower if conventional small 
hypothesis testing experiments were done. Furthermore, the promise of 
the widespread ability to serially profile genomic, transcriptomic and 
epigenetic events in cancer cells and in the blood circulation of patients 
has enabled oncologists to help decide when combinations should or 
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can be instituted. Finally, clinical trial designs that reflect the realities 
of toxicity and the use of intermittent dosing, and adaptive trial designs 
to allow the dynamic institution of combinations based on emergence of 
resistance, will greatly accelerate more-effective therapy combinations 
to improve patient care.  
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Figure 1. Clinical impact of drug combinations on the tumour  
The size of the patient tumour is demarcated within the illustrated 
human cartoon. Drugs A and B are colour-coded as shown. While 
drugs in a given combination will have common effects on a proportion 
of clones of tumour cells, they can have differential effects on other 
clones thus influencing clonal evolution owing to selective pressure. 
The ultimate common readout is the size of the tumour and its rate of 
growth that eventually translates to progression-free survival and 
overall survival. The effects of clinically used combinations can be 
broadly classified as synthetically lethal, synergistic, additive, or mildly 
antagonistic.   
 
Figure 2.  The challenge of optimising drugs dosed in 
combinations 
A) Left panel shows the traditional rule-based dose-escalation 
strategy for combinations based on toxicity. A starting dose is 
selected utilising a combination of a fraction of the maximum tolerated 
dose (MTD) of Drug A with a fraction of the MTD of Drug B.  Each drug 
is in turn escalated in the dose-escalation approach depending on 
tolerability. Green shaded cubes mark the starting dose for the 
combination with proposed dose-escalation steps marked with red 
arrows. Cubes are coded for tolerability as marked in the key, with the 
black curve indicating a hypothetical envelope of tolerability. Right 
panel illustrates a real-life example of the complicated intricacies 
of dose-finding [25]. The MTD of selumetinib and MK-2206 are as 
indicated, with the grey bars indicating doses where target inhibition is 
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seen. The green box mark the starting dose for the combination, with 
the red arrows marking the multiple de-escalation and re-escalation 
steps required to find a tolerable dose. Abbreviations: od = once daily; 
bd = twice daily  
 
B) Combination dose-finding schema based on attaining adequate 
target inhibition. The optimal biological doses (OBD) are pre-defined 
based on pharmacological parameters, for example, target saturation 
of the drug, or optimal target modification of downstream pathways. 
Drug A is given at its recommended dose, with escalating doses of 
Drug B with the aim of reaching its OBD. The arrows indicate proposed 
steps for escalation with the cubes coded for tolerability as shown. 
Cubes are coded as in A) above.  
 
C) Novel combination dose-finding schema [Au: Title too long, so 
I’ve added to the legend] In this novel combination scheme, the fixed 
OBDs of each drug are used but and are given in an increasing 
schedule to ensure drug tolerability. Drug A is given at its 
recommended dose and schedule, while Drug B is given at its 
recommended dose but for only one day a week. If tolerable, the 
number of dosing days is increased with each cohort until the 
recommended schedule is attained. This strategy aims to hit both 
targets hard, but in a tolerable schedule aiming to avoid the problems 
of sub-optimal target blockade.   
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Figure 3. The future: proposed clinical trial designs to overcome 
resistance. Patients are their tumours are profiled using -omics 
technology as shown and various strategies proposed for each 
hypothetical scenario A) Should profiling indicate a degree of de-novo 
resistance to the proposed Drug A, in which case, could it be reversed 
by addition of Drug B,  and the combination used up-front. B) Should 
profiling indicate sensitivity to Drug A, but preclinical models and 
system biology predict the eventual rewiring of signalling networks 
causing resistance, Drug A can be combined with Drug C that has a 
broader epigenetic role. C) Co-clinical strategies employing patient-
derived xenografts alongside prospective longitudinal monitoring of 
circulating cell-free DNA (cfDNA) in patients treated with Drug A. At the 
earliest sign of the development of resistant clones, Drug B is added in 
combination with continuation of the PDXs in a co-clinical trial and 
cfDNA monitoring. With emergence of an alternative mechanism of 
acquired resistance, Drug D can be added to the cocktail of Drug A & 
B, or the patient could be switched to a combination of Drug A & D.  
The black arrows are timelines, with the coloured bars indicating the 
various drugs described as colour coded. 
[Au: I have removed Box 1 as this is just repeating the subheadings in 
the text. However, I think a Box of glossary items could be useful. 
Suggested terms include synthetic lethality, Synergistic  
Additive etc.  
 
Table 
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Examples of toxicities seen in combinations of novel anticancer agents. 
Toxicities could be attributable to one or both drugs. Toxicities could be 
additive or supra-additive (rare with either drug but significant in the 
combination). Rarely the combination can reduce the incidence of  
toxicity  seen with one of the drugs. 
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Overlapping 
mechanisms 
Drug combination  Toxicity (grade 3–4) Comment  Refere
nce 
Majority of the 
toxicity in the 
combination 
attributable to one 
drug in the 
combination  
Everolimus + 
exemestane  
Stomatitis, rash, 
fatigue, diarrhoea 
Toxicity 
attributable to 
everolimus 
making the 
combination 
more toxic than 
aromatase 
inhibitor alone 
[116] 
Overlapping 
toxicity of the 
combination 
attributable to 
each drug 
MEK inhibitor + 
AKT inhibitor 
Skin rash, diarrhoea  Overlapping 
toxicity of each 
drug  
[25] 
Significant non- 
overlapping  
toxicity in addition 
to overlapping 
toxicity  
Ipilimumab + 
Nivolumab 
Transaminitis 
 
 
Unusual with 
either drug but 
significantly 
greater in the 
combination 
[117] 
Diarrhoea, fatigue, 
rash 
Seen with both 
drugs but additive 
or greater than 
additive in the 
combination 
Significant non-
overlappint toxicity 
and overlapping 
toxicity and also 
reduction of 
certain toxicities 
BRAF inhibitor + 
MEK inhibitor 
Pyrexia 
 
 
 
 
 
Unusual with 
either drug but 
significantly 
greater in the 
combination 
[118] 
Fatigue, diarrhoea 
 
Expected 
overlapping 
toxicity  
Keratoacanthoma/sq
uamous carcinoma of 
skin 
Incidence lower 
in the 
combination 
compared to 
BRAF inhibitors 
alone 
 
  39 
GLOSSARY 
Basket trials are a new and evolving form of clinical trial design and 
are predicated on the hypothesis that the presence of a molecular 
marker predicts response to a targeted therapy independent of tumor 
histology. 
 
Synthetic lethality originates from studies in Drosophila model 
systems in which a combination of mutations in two or more separate 
genes leads to cell death and exploits inherent differences between 
cancer cells and normal cells. In the drug development scene, this has 
expanded to included scenarios where drugs as single agents have 
minimal effects, but have significant anti-tumor activity in combination.  
 
Synergy refers to the scenario where one or all partners in a 
combination have some clinical activity, but the sum of the clinical 
activity of the combination is greater than the effect of each drug 
 
Additivity refers to the scenario where each partner in a combination 
has some clinical activity, and the effect on the tumour is equal to the 
sum of activities of both drugs.  
 
Mild antagonism refers to the scenario where one or all partners in a 
combination have some clinical activity, but the sum of the clinical 
activity of the combination is less than the sum of activity of each 
individual drug 
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Systems biology is the computational and mathematical modelling of 
complex biological systems. In the context of drug development, these 
approaches aim to advance the prediction of effective drug combinations 
and the most common strategies include computational modelling, gene 
signature analysis, functional genomics, and high-throughput drug 
combination screening.[119] 
 
Computational modellling of signaling networks is an important tool 
for increasing understanding of pathological signalling networks and 
prioritizing drug targets to test experimentally. Through model 
simulations, one can predict the relative importance of various proteins 
in the network, the presence of signal amplification, and the role of 
feedback and cross-talk.  
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